BR0111596A - Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças - Google Patents

Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças

Info

Publication number
BR0111596A
BR0111596A BR0111596-0A BR0111596A BR0111596A BR 0111596 A BR0111596 A BR 0111596A BR 0111596 A BR0111596 A BR 0111596A BR 0111596 A BR0111596 A BR 0111596A
Authority
BR
Brazil
Prior art keywords
compound
group
denotes
preventing
pharmaceutical composition
Prior art date
Application number
BR0111596-0A
Other languages
English (en)
Other versions
BRPI0000596B8 (pt
BRPI0111596B8 (pt
BRPI0111596B1 (pt
Inventor
Satoshi Nagato
Kohshi Ueno
Koki Kawano
Yoshihiko Norimine
Koichi Ito
Takahisa Hanada
Masataka Ueno
Hiroyuki Amino
Makoto Ogo
Shinji Hatakeyama
Yoshio Urawa
Hiroyuki Naka
Anthony John Groom
Leanne Rivers
Terence Smith
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022483A external-priority patent/GB0022483D0/en
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of BR0111596A publication Critical patent/BR0111596A/pt
Publication of BRPI0111596B1 publication Critical patent/BRPI0111596B1/pt
Publication of BRPI0000596B8 publication Critical patent/BRPI0000596B8/pt
Publication of BRPI0111596B8 publication Critical patent/BRPI0111596B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO E SEU USO, PROCESSO PARA SUA PRODUçãO, COMPOSIçãO FARMACêUTICA E PROCESSO E MéTODO PARA PREVENIR OU TRATAR DOENçAS". A presente invenção fornece um novo composto tendo uma excelente ação inibidora do receptor de AMPA e/ou ação inibidora do cainato. Um composto representado pela seguinte fórmula, um sal ou hidratos do mesmo. Na fórmula, Q indica NH, O ou S; e R^ 1^, R^ 2^ R^ 3^, R^ 4^ e R^ 5^ são iguais ou diferentes um do outro e cada qual indica átomo de hidrogênio, um átomo de halogênio, um grupo de C~ 1-6~ alquila ou um grupo representado pela fórmula -X-A (onde X indica uma ligação simples, um grupo de C~ 1-6~ alquileno opcionalmente substituído ou similares; e A indica um grupo de hidrocarbocíclico aromático de C~ 6-14~ opcionalmente substituído ou grupo heterocíclico aromático de 5 a 14 membros.
BRPI0111596A 2000-06-12 2001-06-08 Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto BRPI0111596B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000175966 2000-06-12
JP2000-175.966 2000-06-12
GB0022483.2 2000-09-13
GB0022483A GB0022483D0 (en) 2000-09-13 2000-09-13 1 2 Dihydropyridine compounds manufacturing method thereof and use thereof
PCT/JP2001/004857 WO2001096308A1 (fr) 2000-06-12 2001-06-08 Composes 1,2-dihydropyridine, leur procede de preparation et leur utilisation

Publications (4)

Publication Number Publication Date
BR0111596A true BR0111596A (pt) 2004-03-02
BRPI0111596B1 BRPI0111596B1 (pt) 2018-10-02
BRPI0000596B8 BRPI0000596B8 (pt) 2021-05-25
BRPI0111596B8 BRPI0111596B8 (pt) 2022-07-26

Family

ID=26244997

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111596A BRPI0111596B8 (pt) 2000-06-12 2001-06-08 Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto

Country Status (27)

Country Link
US (3) US6949571B2 (pt)
EP (3) EP1300396B1 (pt)
JP (3) JP3922368B2 (pt)
KR (3) KR100904011B1 (pt)
CN (1) CN1245386C (pt)
AT (1) ATE420862T1 (pt)
AU (2) AU2001262723C1 (pt)
BE (1) BE2013C003I2 (pt)
BR (1) BRPI0111596B8 (pt)
CA (1) CA2412172C (pt)
CY (2) CY1108969T1 (pt)
DE (1) DE60137426D1 (pt)
DK (1) DK1300396T3 (pt)
ES (1) ES2320973T3 (pt)
FR (1) FR12C0074I2 (pt)
HK (1) HK1056871A1 (pt)
HU (2) HU1300187D0 (pt)
IL (5) IL152848A0 (pt)
LU (1) LU92113I2 (pt)
MX (1) MXPA02012314A (pt)
NL (1) NL300565I1 (pt)
NO (2) NO325160B1 (pt)
NZ (1) NZ522773A (pt)
PT (1) PT1300396E (pt)
TW (2) TWI292757B (pt)
WO (1) WO2001096308A1 (pt)
ZA (1) ZA200209270B (pt)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949571B2 (en) * 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
HUP0500543A2 (hu) * 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
JP4119114B2 (ja) * 2001-11-28 2008-07-16 広栄化学工業株式会社 新規なジヒドロキシ（３−ピリジル）ボラン類
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP5082033B2 (ja) * 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
DE60326223D1 (de) * 2002-04-19 2009-04-02 Glaxo Group Ltd Verbindungen mit affinität zum 5ht2c-rezeptor und deren therapeutische verwendung
JP4208512B2 (ja) * 2002-07-23 2009-01-14 株式会社クラレ ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法
AU2003274022A1 (en) * 2002-10-17 2004-05-04 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
BR0316785A (pt) * 2002-12-16 2005-10-25 Mitsubishi Pharma Corp Derivados de 4-pirimidona-3-substituìdos
WO2004063151A2 (en) * 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
GB0305024D0 (en) * 2003-03-05 2003-04-09 Glaxo Group Ltd Compounds
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JP2007099781A (ja) * 2004-07-06 2007-04-19 Eisai R & D Management Co Ltd １，２−ジヒドロピリジン化合物の結晶の製造方法
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
EP1831168B1 (en) * 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
US20060188938A1 (en) * 2005-01-07 2006-08-24 Mullan Michael J Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
JPWO2006109876A1 (ja) * 2005-04-08 2008-11-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 不随意運動治療剤
AU2006244072B2 (en) 2005-05-10 2012-09-20 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US8153804B2 (en) * 2005-08-02 2012-04-10 Lexicon Pharmaceuticals, Inc. Aryl pyridines and methods of their use
JP2009506123A (ja) 2005-08-29 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
CN101291926A (zh) * 2005-08-29 2008-10-22 沃泰克斯药物股份有限公司 可用作Tec家族非受体酪氨酸激酶抑制剂的3,5-二取代的吡啶-2-酮
WO2007027594A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
EP1932840B1 (en) 2005-10-03 2014-04-09 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
US20090088574A1 (en) * 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
WO2007072869A1 (ja) * 2005-12-21 2007-06-28 Eisai R & D Management Co., Ltd. １，２－ジヒドロピリジン化合物の非晶質体
JP4865337B2 (ja) * 2006-01-24 2012-02-01 富士フイルムファインケミカルズ株式会社 ２，３’−ビピリジル−６’−オンの製造方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US7718807B2 (en) 2006-04-28 2010-05-18 Eisai R&D Management Co., Ltd. Salt of 1,2-dihydropyridine compound
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
EP2131828A2 (en) * 2007-03-05 2009-12-16 Eisai R&D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
EP2164488A1 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
KR20100096131A (ko) 2007-11-06 2010-09-01 아스트라제네카 아베 특정 2-피라지논 유도체 및 호중구 엘라스타제의 억제제로서의 이의 용도
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101883757B (zh) 2007-12-21 2013-06-12 株式会社可乐丽 6-卤代-3-芳基吡啶衍生物的制备方法
JP2011507799A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇のためのａｍｐａ受容体アンタゴニストおよびゾニサミド
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
MX2010011920A (es) * 2008-05-05 2010-11-26 Amgen Inc Compuestos de urea como moduladores de gamma secretasa.
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
US8859760B2 (en) 2008-07-29 2014-10-14 Frontier Scientific, Inc. Compositions for killing or preventing the growth of microbes
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
WO2010051188A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010072607A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
BRPI0923498A2 (pt) 2008-12-23 2019-09-24 Hoffmann La Roche amidos de diidropiridona como moduladores de p2x7
EP2391604A1 (en) 2008-12-23 2011-12-07 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
RU2012116877A (ru) 2009-10-02 2013-11-10 Астразенека Аб Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US20120142709A1 (en) * 2010-12-06 2012-06-07 Selness Shaun R Substituted pyridinone-pyridinyl compounds
EP3434669B1 (en) 2011-03-04 2020-11-04 Yale University Intermediate compounds utilizable in synthesis of (-) huperzine and process for obtain one of these intermediate compounds
ITMI20111952A1 (it) * 2011-10-27 2013-04-28 Italiana Sint Spa Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel
EP2800747A4 (en) * 2012-01-03 2015-12-09 Mapi Pharma Ltd POLYMORPHY OF PERAMPANEL
CN104254526B (zh) * 2012-03-31 2017-06-20 乔治亚大学研究基金公司 针对结核病的新的抗分枝杆菌药物
WO2014012360A1 (en) 2012-07-18 2014-01-23 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
ITMI20121390A1 (it) 2012-08-06 2014-02-07 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
TW201441193A (zh) 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014163210A1 (en) 2013-04-04 2014-10-09 Eisai R&D Management Co., Ltd. [11 c] and [18f] labeled 1,3-diphenyl-5-(pyrimidin-2-yl)-pyridin-2(1 h)-one derivatives and their use for pet imaging of the ampa receptor
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CN103274993A (zh) * 2013-06-13 2013-09-04 南京工业大学 二氢吡啶和吡咯类杂环的新合成方法
WO2015013520A1 (en) * 2013-07-25 2015-01-29 IVAX International GmbH Process for the preparation of perampanel
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9120777B2 (en) 2013-10-29 2015-09-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103664756A (zh) * 2013-11-26 2014-03-26 苏州晶云药物科技有限公司 吡仑帕奈新晶型a及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
KR20220039824A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
CN105085382B (zh) * 2014-05-14 2019-10-18 江苏豪森药业集团有限公司 吡仑帕奈异构体晶型及其制备方法和用途
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CN103980188B (zh) * 2014-05-30 2016-01-27 浙江永宁药业股份有限公司 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3255042B1 (en) * 2015-02-04 2020-12-30 Beyondbio Inc. Heterocyclic compound and pharmaceutical composition comprising same
US10111867B2 (en) 2015-02-17 2018-10-30 Mapi Pharma Ltd. Process and intermediates for the preparation of perampanel
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2016172333A1 (en) 2015-04-21 2016-10-27 Teva Pharmaceuticals International Gmbh A solid state form of perampanel
AU2016289031C1 (en) 2015-07-06 2019-10-17 Public University Corporation Yokohama City University Novel compound that specifically binds to AMPA receptor
CN105085383B (zh) * 2015-08-19 2017-09-01 四川大学 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
SG11201803433TA (en) * 2015-11-13 2018-05-30 Eisai R&D Man Co Ltd Pyranodipyridine compound
KR101652750B1 (ko) * 2015-12-03 2016-08-31 김종선 피리딘 및 그 유도체의 정제방법
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
EP3541785A4 (en) 2016-11-18 2020-04-01 Dow Agrosciences Llc 4- ((6-BROMOPYRIDIN-3-YL) OXY) BENZONITRILE AND METHODS OF PREPARATION
WO2018114989A1 (en) * 2016-12-22 2018-06-28 Biotronik Ag Intratumoral drug delivery materials and methods for treating breast cancer
JP6241974B1 (ja) 2017-01-11 2017-12-06 公立大学法人横浜市立大学 霊長類生体の脳内ａｍｐａ受容体のイメージング方法、プログラム、及びスクリーニング方法
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combined treatment
CA3108048A1 (en) * 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN110028442B (zh) * 2018-01-11 2020-07-17 新发药业有限公司 一种吡仑帕奈的简便制备方法
GB201803340D0 (en) * 2018-03-01 2018-04-18 Univ Of Sussex Compounds
EP3560934A1 (en) 2018-04-26 2019-10-30 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040
BR112021010953A2 (pt) 2018-12-14 2021-08-24 Eisai R&D Management Co., Ltd. Formulações farmacêuticas de base aquosa de compostos de 1,2-di-hidropiridina
BR112021014583A2 (pt) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. Compostos e utilizações dos mesmos
CN110483563B (zh) * 2019-09-06 2021-12-28 山西医科大学 一种新型离子型β-萘酚醛席夫碱锆配合物的制备方法及应用
KR102392825B1 (ko) 2020-02-18 2022-04-29 명인제약주식회사 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 ｌ-말릭산의 공결정 화합물 및 이의 제조 방법
CN111362930B (zh) * 2020-04-15 2023-02-03 安徽医科大学 一种1，2，4-噁二唑-吡啶类化合物及其应用
JPWO2023042887A1 (pt) 2021-09-15 2023-03-23
JPWO2023042888A1 (pt) 2021-09-15 2023-03-23
CN116265440B (zh) * 2021-12-16 2024-09-27 贵州大学 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2024010585A1 (en) * 2022-07-07 2024-01-11 Yale University Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
KR20240008565A (ko) * 2022-07-12 2024-01-19 이화여자대학교 산학협력단 연속 흐름 공정을 포함하는 페람파넬 유도체의 제조 방법
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283761A (en) * 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivative
JPS5531072A (en) * 1979-07-30 1980-03-05 Rikagaku Kenkyusho Preparation of 2-pyridone compound
DE4003541C1 (pt) 1990-02-06 1991-08-08 Alter S.A., Madrid, Es
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
CA2199468C (en) 1994-09-27 2006-06-06 Jun-Ichi Shishikura 1,2,3,4-tetrahydroquinoxalinedione derivative
WO1996033974A1 (fr) * 1995-04-27 1996-10-31 The Green Cross Corporation Composes heterocycliques amides et leur utilisation medicinale
WO1997018163A1 (en) 1995-11-15 1997-05-22 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite p1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
PT901487E (pt) 1996-05-15 2003-08-29 Pfizer 4(3h)-quinazolinonas 2,3,6-trissubstituidas
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
KR100476586B1 (ko) 1996-12-05 2005-03-18 암젠 인코포레이티드 치환된 피리미딘온 화합물과 이 화합물을 포함하는 제약학적 조성물 및 치료방법
ID22711A (id) 1997-02-28 1999-12-09 Pfizer Prod Inc Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa
GB9708945D0 (en) * 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
AU1504599A (en) 1997-12-17 1999-07-05 Shionogi & Co., Ltd. Novel pyridine compounds
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
US6949571B2 (en) 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses

Also Published As

Publication number Publication date
US20090275751A1 (en) 2009-11-05
AU6272301A (en) 2001-12-24
AU2001262723C1 (en) 2006-05-11
IL184687A (en) 2010-06-30
HU229553B1 (en) 2014-01-28
TWI321565B (pt) 2010-03-11
US7563811B2 (en) 2009-07-21
BE2013C003I2 (pt) 2020-08-20
DE60137426D1 (de) 2009-03-05
KR100869271B1 (ko) 2008-11-18
NL300565I2 (pt) 2016-01-18
LU92113I2 (fr) 2013-02-12
HU1300187D0 (hu) 2004-03-01
CA2412172A1 (en) 2002-12-06
AU2001262723B2 (en) 2005-05-12
NO20025955L (no) 2003-02-12
BRPI0000596B8 (pt) 2021-05-25
US20050245581A1 (en) 2005-11-03
TWI292757B (pt) 2008-01-21
US6949571B2 (en) 2005-09-27
EP1300396A4 (en) 2005-06-15
PT1300396E (pt) 2009-04-20
EP1300396A1 (en) 2003-04-09
JP3922368B2 (ja) 2007-05-30
CN1436172A (zh) 2003-08-13
JP2012207021A (ja) 2012-10-25
FR12C0074I1 (pt) 2013-01-18
DK1300396T3 (da) 2009-04-06
CN1245386C (zh) 2006-03-15
US20040023973A1 (en) 2004-02-05
IL184686A (en) 2010-05-17
HUP0303398A2 (hu) 2004-03-01
JP5068069B2 (ja) 2012-11-07
NL300565I1 (pt) 2016-01-18
US7939549B2 (en) 2011-05-10
ES2320973T3 (es) 2009-06-01
TW200815402A (en) 2008-04-01
IL184687A0 (en) 2007-12-03
IL192605A (en) 2012-06-28
KR100850728B1 (ko) 2008-08-06
EP1300396B1 (en) 2009-01-14
IL192605A0 (en) 2009-02-11
WO2001096308A1 (fr) 2001-12-20
BRPI0111596B8 (pt) 2022-07-26
EP2177520A1 (en) 2010-04-21
IL152848A (en) 2007-09-20
IL184686A0 (en) 2007-12-03
KR20030012882A (ko) 2003-02-12
CY2012032I2 (el) 2015-08-05
EP2053041A2 (en) 2009-04-29
JPWO2001096308A1 (ja) 2004-01-08
NO20025955D0 (no) 2002-12-11
KR20070094995A (ko) 2007-09-27
KR100904011B1 (ko) 2009-06-22
CA2412172C (en) 2012-07-24
NO2012021I1 (no) 2013-01-07
KR20070094994A (ko) 2007-09-27
FR12C0074I2 (fr) 2013-08-16
IL152848A0 (en) 2003-06-24
HUP0303398A3 (en) 2010-03-29
JP2007119486A (ja) 2007-05-17
BRPI0111596B1 (pt) 2018-10-02
NZ522773A (en) 2005-06-24
ATE420862T1 (de) 2009-01-15
EP2053041A3 (en) 2009-07-29
ZA200209270B (en) 2005-08-31
CY1108969T1 (el) 2014-07-02
NO2012021I2 (no) 2013-09-09
HK1056871A1 (en) 2004-03-05
NO325160B1 (no) 2008-02-11
CY2012032I1 (el) 2014-07-02
MXPA02012314A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
NO20045369L (no) Nye, substituerte sulfamatanticonvulsivaderivater
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
ATE377004T1 (de) Proteinkinaseinhibitoren
DE60331187D1 (de) Kinaseinhibitoren
DE60009511D1 (de) Nematizide trifluorbutene
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
NO20045486L (no) Nye forbindelser og deres anvendelse
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BRPI0407841A (pt) inibidores heterocìclicos de quinase
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
ATE304522T1 (de) Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DE50203353D1 (de) 1,3-dihydroxybenzol-derivate und diese verbindungen enthaltende färbemittel
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
EA200100918A1 (ru) Агонисты 5-ht1f рецептора
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
BR0317363A (pt) Antagonista de npy-5

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI R AND D MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CL. C07D213/64, 213/69, 213/81, 213/84, 213/89, 401/04, 401/14, 405/04, 405/14, 409/04, 4"09/14, 413/04, 413/14, 417/04, 417/14, 471/04, 471/06 "9, 31/444, 31/4545, 31/4709, 31/4725 6, 25/18, 25/28, 25/30, 43/00, 9/10

Ipc: C07D 213/64 (2011.01), C07D 213/69 (2011.01), C07D

Free format text: PARA:INT.CL. C07D213/64, 213/69, 213/81, 213/84, 213/89, 401/04, 401/14, 405/04, 405/14, 409/04, 409/14, 413/04, 413/14, 417/04, 417/14, 471/04, 471/06; A61K31/4422, 31/443, 31/4433, 31/4436, 31/4439, 31/444, 31/4545, 31/4709, 31/4725; A61P1/00, 1/08, 13/02, 25/00, 25/02, 25/04, 25/08, 25/14, 25/16, 25/18, 25/28, 25/30, 43/00, 9/10

Ipc: C07D 213/64 (2011.01), C07D 213/69 (2011.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2673 DE 29/03/2022 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2491 DE 02/10/2018 QUANTO AO PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF )

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/06/2021